Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Apoptosis >> PD-1/PD-L1 interaction

PD-1/PD-L1 interaction

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

Products for  PD-1/PD-L1 interaction

  1. Cat.No. Product Name Information
  2. GC50482 (D)-PPA 1 PD-1/PD-L1 interaction inhibitor (D)-PPA 1 Chemical Structure
  3. GC66337 Anti-Mouse PD-L1 Antibody Anti-Mouse PD-L1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host Rat. Anti-Mouse PD-L1 Antibody Chemical Structure
  4. GC32704 Atezolizumab (MPDL3280A) Atezolizumab (MPDL3280A) (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research. Atezolizumab (MPDL3280A) Chemical Structure
  5. GC31719 Avelumab (Anti-Human PD-L1, Human Antibody) Avelumab (Anti-Human PD-L1, Human Antibody) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. Avelumab (Anti-Human PD-L1, Human Antibody) Chemical Structure
  6. GC25160 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 Chemical Structure
  7. GC38740 BMS-1001 hydrochloride BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride Chemical Structure
  8. GC31753 BMS-1166 (PD-1/PD-L1-IN1) BMS-1166 (PD-1/PD-L1-IN1) is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 (PD-1/PD-L1-IN1) Chemical Structure
  9. GC38131 BMS-1166 hydrochloride BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride Chemical Structure
  10. GC62682 BMSpep-57 hydrochloride BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs. BMSpep-57 hydrochloride Chemical Structure
  11. GC62253 Camrelizumab

    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab?binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as?anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.

     Camrelizumab Chemical Structure
  12. GC35913 Durvalumab

    A humanized anti-PD-L1 monoclonal antibody

     Durvalumab Chemical Structure
  13. GC66344 Envafolimab Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors. Envafolimab Chemical Structure
  14. GC38044 Fraxinellone Fraxinellone Chemical Structure
  15. GC68404 Human PD-L1 inhibitor IV Human PD-L1 inhibitor IV Chemical Structure
  16. GC69677 MAX-10181

    MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor with an IC50 value of 0.018 μM. MAX-10181 can be used for research on cancer and other related diseases.

     MAX-10181 Chemical Structure
  17. GC34218 Nivolumab (BMS-936558) Nivolumab (BMS-936558) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer. Nivolumab (BMS-936558) Chemical Structure
  18. GC36767 NP-12 NP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. NP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs). NP-12 Chemical Structure
  19. GC36768 NP-12 (TFA) NP-12 (TFA) Chemical Structure
  20. GC65266 Onvatilimab Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity. Onvatilimab Chemical Structure
  21. GC19225 PD-1-IN-1 (CA-170) PD-1-IN-1 (CA-170) is an orally delivered dual inhibitor of VISTA and PD-L1. PD-1-IN-1 (CA-170) Chemical Structure
  22. GC34928 PD-1-IN-17 An inhibitor of PD-1 signaling PD-1-IN-17 Chemical Structure
  23. GC34929 PD-1-IN-17 TFA PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 TFA Chemical Structure
  24. GC36862 PD-1-IN-22 PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM. PD-1-IN-22 Chemical Structure
  25. GC63517 PD-1-IN-24 PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor. PD-1-IN-24 Chemical Structure
  26. GC15142 PD-1/PD-L1 inhibitor 1 (BMS-1) PD-1/PD-L1 inhibitor 1 (BMS-1) is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM). PD-1/PD-L1 inhibitor 1 (BMS-1) Chemical Structure
  27. GC16762 PD-1/PD-L1 inhibitor 2 PD-1/PD-L1 inhibitor 2 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. PD-1/PD-L1 inhibitor 2 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. PD-1/PD-L1 inhibitor 2 has antitumor activity. PD-1/PD-L1 inhibitor 2 Chemical Structure
  28. GC16258 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1 Inhibitor 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1 Inhibitor 3 can be used for the research of various diseases, including cancer and infectious diseases. PD-1/PD-L1 Inhibitor 3 Chemical Structure
  29. GC65071 PD-1/PD-L1-IN 3 TFA PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases. PD-1/PD-L1-IN 3 TFA Chemical Structure
  30. GC62658 PD-1/PD-L1-IN 7 PD-1/PD-L1-IN 7 (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 Chemical Structure
  31. GC62125 PD-1/PD-L1-IN-10 PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. PD-1/PD-L1-IN-10 Chemical Structure
  32. GC69673 PD-1/PD-L1-IN-13

    PD-1/PD-L1-IN-13 (Compound 43) is an effective immune checkpoint PD-1/PD-L1 inhibitor, with an IC50 value of 10.2 nM for the interaction between PD-1/PD-L1. PD-1/PD-L1-IN-13 promotes CD8+ T cell activation and delays tumor growth in Hepa1-6 mouse models.

     PD-1/PD-L1-IN-13 Chemical Structure
  33. GC69674 PD-1/PD-L1-IN-14

    PD-1/PD-L1-IN-14 (compound 17) is an inhibitor of the interaction between PD-1 and PD-L1, with an IC50 value of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits the interaction between PD-1 and PD-L1, promotes dimerization, endocytosis, and degradation of PD-L1.

     PD-1/PD-L1-IN-14 Chemical Structure
  34. GC64855 PD-1/PD-L1-IN-23 PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice. PD-1/PD-L1-IN-23 Chemical Structure
  35. GC69676 PD-1/PD-L1-IN-29

    PD-1/PD-L1-IN-29 (S4-1) is an effective PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 can bind to PD-L1 and disrupt the interaction between PD-1 and PD-L1, inducing dimerization and internalization of PD-L1, improving its localization in the endoplasmic reticulum, and promoting entry into the endoplasmic reticulum. PD- 1/PD-LI-IN -29 has anti-cancer activity.

     PD-1/PD-L1-IN-29 Chemical Structure
  36. GC62688 PD-1/PD-L1-IN-8 PD-1/PD-L1-IN-8 (PD-1/PD-L1-IN-8; example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. PD-1/PD-L1-IN-8 Chemical Structure
  37. GC62387 PD-1/PD-L1-IN-9 PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. PD-1/PD-L1-IN-9 Chemical Structure
  38. GC67694 PD-1/PD-L1-IN-9 hydrochloride PD-1/PD-L1-IN-9 hydrochloride Chemical Structure
  39. GC62502 PD-1/PD-L1-IN-NP19 PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 Chemical Structure
  40. GC63984 PD-L1-IN-1 PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells. PD-L1-IN-1 Chemical Structure
  41. GC31878 PD1-IN-2 PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator. PD1-IN-2 Chemical Structure
  42. GC65920 PD1-PDL1-IN 1 PD1-PDL1-IN 1 is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator. PD1-PDL1-IN 1 Chemical Structure
  43. GC69675 PD1-PDL1-IN 1 TFA

    PD1-PDL1-IN 1 TFA (compound 16) is an effective inhibitor of programmed cell death 1 (PD-1). PD1-PDL1-IN 1 TFA can be used as an immunomodulatory agent.

     PD1-PDL1-IN 1 TFA Chemical Structure
  44. GC19531 Pembrolizumab

    Pembrolizumab has demonstrated clinically significant anti-tumor activity with acceptable safety in patients with advanced solid cancers

     Pembrolizumab Chemical Structure
  45. GC66394 Penpulimab Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. Penpulimab Chemical Structure
  46. GC66378 Serplulimab Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. Serplulimab Chemical Structure
  47. GC65290 Sintilimab Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab Chemical Structure
  48. GC69934 Spartalizumab

    Spartalizumab (PDR001) is a humanized monoclonal antibody that binds to PD-1 with high affinity and blocks its interaction with PD-L1 and PD-L2. It can be used for the study of anaplastic thyroid cancer (ATC).

     Spartalizumab Chemical Structure
  49. GC65580 Sugemalimab Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research. Sugemalimab Chemical Structure
  50. GC10469 Sulfamethoxypyridazine long-acting sulfonamide antibiotic Sulfamethoxypyridazine Chemical Structure
  51. GC65033 Tislelizumab

    Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy.

     Tislelizumab Chemical Structure
  52. GC19131 Tomivosertib eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib Chemical Structure
  53. GC64561 Toripalimab

    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.

     Toripalimab Chemical Structure
  54. GC61946 TPP-1 TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function. TPP-1 Chemical Structure
  55. GC70137 Vudalimab

    Vudalimab is an effective PD-1 and CTLA-4 dual inhibitor, which is a fully humanized bispecific monoclonal antibody. Vudalimab targets the immune checkpoint receptors PD-1 and CTLA-4, promoting selective T cell activation against tumors.

     Vudalimab Chemical Structure
  56. GC70145 WL12

    WL12 is a specific targeted programmatic death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled with different radioactive isotopes to produce a radiotracer for evaluating the expression of PD-L1 in tumors.

     WL12 Chemical Structure

55 Item(s)

per page

Set Descending Direction